EXOVENT-PA NEGATIVE PRESSURE VENTILATOR
BREATHING NEW LIFE INTO RESPIRATORY CARE
Illustrious Healthcare Solutions are marketing Exovent-PA on behalf of Portsmouth Aviation as part of our collaboration.
Exovent-PA is a groundbreaking Negative Pressure Ventilator which provides external ventilation for patients with respiratory disease. It is designed to support natural breathing without the need for invasive procedures. Now in development, this device aims to offer an alternative to current ventilation methods, enhancing comfort and quality of care.
Developed with support from the Exovent charity, the Exovent-PA is inspired by the proven principles of negative pressure ventilators and reimagines this approach in a modern, patient-friendly design. We are currently (Q3 2024) in the advanced stages of finalising the control system, with preparations underway for first-in-human clinical investigations. This marks a significant step forward in bringing this life-saving technology to those who need it most.
Continue scrolling to discover more about Exovent-PA and its potential to transform respiratory care.
Please CONTACT US for further information.
Our Journey to Market
"At UCLH, we believe Exovent to be an important advance in the way we could manage respiratory failure. We are delighted to be working with Portsmouth Aviation to support the clinical evaluation of the finished Exovent."
Dr David Brealey
Consultant in Anaesthesia and Intensive Care Medicine
Key Features of Exovent-PA
- Non-Invasive: Supports natural breathing without the need for intubation.
- Patient Comfort: Allows for speaking while under treatment, with an adjustable bed backrest for extra comfort.
- Compact Design: Fits easily within a hospital bed setup, allowing full access for healthcare professionals and has a small storage footprint.
- Innovative Control System: Advanced controls for tailored respiratory support.
- Ease of Use: Designed with healthcare professionals input for quick setup and operation.
Learn how we can transform patient care. CONTACT UStoday!
About Exovent-PA
The Exovent charity is a group of eminent medical professionals, scientists, engineers, academics, business professionals and manufacturers that champion negative pressure ventilation as a therapy method for treatment of respiratory disease patients globally. Its vision is a world where those with a respiratory disease have access to non-invasive negative pressure breathing support when they need it.
Since 2021, Exovent have been collaborating with Portsmouth Aviation to bring Exovent-PA to market. This partnership combines the vision of the charity with Portsmouth Aviation's engineering expertise, working together to develop a device that can revolutionise the treatment of respiratory conditions globally.
History of Ventilators
How is Exovent-PA different?
Current negative pressure ventilators are not sufficiently state-of-the-art to gain traction in healthcare trusts. Cuirass devices only provide limited efficiency and full body units are unwieldy so difficult to use. Exovent-PA overcomes both of these challenges.
Non-invasive ventilation can significantly reduce mortality rates. Positive pressure ventilation is the current norm; however, achieving a leak-free facemask fit is difficult, poorly tolerated by patients and makes eating & speaking difficult.
Facemask intolerance affects 30–50% of patients, causing failure in ~25%. Lesions occur at contact points in 100% of patients after 48hr of mask use.
If non-invasive positive pressure ventilation is not tolerated, the next step is intubation.
Unlike traditional positive pressure ventilators, which push air into the lungs, Exovent-PA helps to naturally draw air in by creating a partial vacuum around the chest. This not only reduces the risk of lung injury, but also enhances quality of care.
"When you relax, you can really feel it helping you breath. I was amazed how effective it was."
Professor David Howard
Honorary Consultant and Professor of Head and Neck Oncology
Exovent-PA & COPD
A primary function of Exovent-PA is to treat patients with Chronic Obstructive Pulmonary Disease (COPD). This currently places a significant burden on the NHS. Over 3 million suffer from the disease in the UK, with 115,000 emergency admissions annually, and 24,000 deaths.
Clinical trials have shown that the duration of ventilation whilst on negative pressure compared to positive pressure can be dramatic. Time under treatment was significantly lower in cases (negative) than in controls (positive), with a median of 16 hours (range 2-111 hrs) versus 96 hours (range 12-336 hrs).
